Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Biotechnology
Aizen Therapeutics, an AI-driven biotech headquartered in San Diego, has officially launched from stealth mode, introducing its drug discovery platform, DaX. 21 November 2024
Biotechnology
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s Halozyme Therapeutics has submitted a non-binding proposal to acquire Evotec for 11.00 euros per share in cash, implying a fully-diluted equity value of around 2.0 billion euros ($2.12 billion). 15 November 2024
Biotechnology
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Although it is seeing a downturn in sales and profits, German biotech BioNTech is continuing to acquire assets with the cash pile it made through the covid pandemic, notably iis Comirnaty vaccine that was developed with Pfizer (NYSE: PFE). 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Pharmaceutical
Drugmaker Cipla is to acquire an 11.7% stake in digital therapeutics company Wellthy Therapeutics. 19 February 2019
Pharmaceutical
India’s Bharat Biotech today announced plans to acquire Chiron Behring Vaccines, located in Ankleshwar, Gujarat. 15 February 2019
Pharmaceutical
In the wake of its takeover of Shire, Japanese drugmaker Takeda (TYO: 4502) has announced it has filed paperwork for the issuance of a 500 billion yen ($4.5 billion) bond. 15 February 2019
Pharmaceutical
India’s Glenmark Pharmaceuticals says that that its board of directors has given an in-principle approval to spin off the innovation business into a new company in the USA. Setting up of the new company will provide an enhanced focus to the innovation business and help accelerate the pipeline towards commercialization. 15 February 2019
Pharmaceutical
Axovant Sciences, a clinical-stage company developing innovative gene therapies, today announced the formation of Arvelle Therapeutics and the strategic transition of its legacy small molecule team into the newly-formed company. 14 February 2019
Pharmaceutical
Australian medicinal cannabis company Althea has announced it is launching a UK-based subsidiary aimed at leveraging its experience as a supplier of cannabis-based pharmaceutical products. 13 February 2019
Pharmaceutical
As is often the case, the first month of the year featured one or two eye-watering M&A deals. 11 February 2019
Biotechnology
In a second collaboration within a year with a pharma major, US specific antibody therapeutics company Tenebio has today announced a collaboration with AbbVie. 11 February 2019
Biosimilars
South Korea’s Samsung Bioepis, a joint venture between the Korean conglomerate Samsung and US biotech Biogen, has said it is expanding in mainland China through a licensing agreement with C-Bridge Capital. 11 February 2019
Biotechnology
Japanese biotech Sosei Heptares Group has announced an agreement with Medicxi, a venture fund dedicated to financing asset-centric firms, to form two independent companies, Orexia and Inexia. 4 February 2019
Pharmaceutical
Spain-based specialty drugmaker Neuraxpharm Group, focused on the treatment of central nervous system disorders (CNS), has acquired Farmax. 1 February 2019
Pharmaceutical
Bristol-Myers Squibb takeover target Celgene has impressed investors with a better-than-forecast result for the last three months of 2018, propelled largely by psoriasis drug Otezla (apremilast). 31 January 2019
Biotechnology
US biotech firm Aldeyra Therapeutics today announced that it has acquired Helio Vision, a privately held biotechnology company. 29 January 2019
Generics
Italian active pharmaceutical ingredients (API) contract development and manufacturing organization (CDMO) Olon SpA and generics supplier, today announced the acquisition of Capua BioServices SpA, a global provider of CDMO services in the field of microbial fermentation. 25 January 2019
Biotechnology
German immunotherapeutics specialist BioNTech has reached agreement with fellow Germany-based MAB Discovery to acquire the latter’s operational antibody generation unit. 23 January 2019
Pharmaceutical
Nevada, USA-based Spectrum Pharmaceuticals says it has agreed terms to sell seven FDA-approved hematology/oncology products to Acrotech Biopharma, of New Jersey, USA. 18 January 2019
Biotechnology
A start-up that was founded by a group of investors led by Pablo Legorreta, the chief executive of biopharma investor Royalty Pharma, has announced the $62 million acquisition of inRegen and its affiliate, Twin City Bio. 14 January 2019
Pharmaceutical
There was further clear evidence of major M&A activity in the start of the New Year, with Eli Lilly announcing it has agreed an $8 billion deal to acquire Loxo Oncology, following swiftly on the previous week’s $74 billion deal from Bristol-Myers to buy biotech Celgene. On the research front, Axsome impressed with mid-stage results for its major depressive disorder drug AXS-05. And among deal-making, Gilead Sciences entered into another NASH collaboration, this one with South Korea’s Yuhan Corp. 13 January 2019
Biotechnology
Following the announcement of Eli Lilly’s acquisition of Loxo Oncology, which marks the second multi-billion-dollar deal in 2019, Volkan Gunduz, senior oncology and hematology analyst at analytics firm GlobalData, offers his views on the deal. 9 January 2019
Pharmaceutical
Canada-headquartered Generex Biotechnology has completed the acquisition of 51% of USA-based Regentys, a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. 8 January 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze